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Meditative Movement as a treatment 
for Pulmonary Dysfunction in Flight 
Attendants Exposed to second-Hand 
cigarette smoke: study Protocol 
for a randomized trial
Peter Payne1* , David Zava2 , Steven Fiering1 and Mardi Crane-Godreau1
1 Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA, 2 ZRT Laboratory, Beaverton,  
OR, USA
A study protocol is presented for the investigation of meditative movement (MM) as 
a treatment for pulmonary dysfunction in flight attendants (FA) who were exposed to 
second-hand cigarette smoke while flying before the smoking ban. The study will have 
three parts, some of which will run concurrently. The first is a data gathering and screen-
ing phase, which will gather data on pulmonary and other aspects of the health of FA, 
and will also serve to screen participants for the other phases. Second is an exercise 
selection phase, in which a variety of MM exercises will be taught, over a 16-week 
period, to a cohort of 20 FA. A subset of these exercises will be selected on the basis of 
participant feedback on effectiveness and compliance. Third is a 52-week randomized 
controlled trial to evaluate the effectiveness of a digitally delivered form of the previously 
selected exercises on a group of 20 FA, as compared with an attention control group. 
Outcome measures to be used in all three parts of the study include the 6-min walk 
test as a primary measure, as well as a range of biomarkers, tests, and questionnaires 
documenting hormonal, cardio-respiratory, autonomic, and affective state. This study is 
registered at ClinicalTrials.gov. Identifier: NCT02612389.
Keywords: meditative movement, Qigong, flight attendants, second-hand cigarette smoke, pulmonary 
dysfunction, coPD, autonomic nervous system, inflammation
BAcKGroUND
coPD and Its co-Morbidities in FA
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality 
worldwide; the primary cause of COPD is exposure to cigarette smoke. Those exposed to second-
hand cigarette smoke (SHCS) are at increased risk for respiratory, cardiovascular, and other organ 
system disease that are similar to those suffered by smokers (1). Many flight attendants (FA) who 
flew before the ban on smoking in commercial aircraft, and who were thus exposed to SHS, have 
abnormal pulmonary function consistent with mild COPD, despite not meeting the GOLD criteria 
of reduced FEV1/FVC ratio (2). They also show increased rates of many of the co-morbidities associ-
ated with COPD, such as chronic bronchitis, cardiovascular disease, skin cancer, and depression 
and anxiety (3). The co-morbidities of COPD exacerbate and are exacerbated by the COPD (4). 
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Thus, consideration of the co-morbidities of COPD is an essential 
aspect of its treatment (4). Significant co-morbidities include 
cardiovascular disease (4); depression and anxiety (5); muscle 
weakness, osteoporosis, skin and lung cancer, and diabetes (4); 
as well as autonomic disturbance (6), systemic inflammation and 
cachexia (4); frequent hypoxia, dyspnea, and disturbed breath-
ing patterns (7); and disturbed posture and movement (8); see 
Figure 1.
the Autonomic Nervous system in coPD
Autonomic dysfunction (AD) is known to be associated with 
COPD and most of its co-morbidities (6, 9–15); see Figure  2. 
Most of the diseases known to be co-morbidities of COPD may 
be caused or exacerbated by AD; for instance, cardiovascular 
disease (15, 16); hypoxia (17, 18); disturbed respiratory patterns 
(7, 19, 20); disturbed posture and movement patterns (21, 22); 
diabetes (17); immune function (4); airways restriction (6, 23); 
and anxiety and depression (12).
Meditative Movement
Qigong, a traditional Chinese health practice, has been used in 
China for hundreds of years in treating those with respiratory 
disease (24). Recently, a case has been made for a novel category 
of exercise “meditative movement,” (MM) of which Qigong, Tai 
Chi, and Hatha Yoga are examples (25). Significantly, MM is 
hypothesized to act via its effect on the autonomic nervous system 
(ANS) (26, 27), as well as on neuromuscular control (28,  29), 
musculoskeletal condition (30), and mental state (31).
Meditative movement has been shown to be an effective 
intervention for COPD (30, 32–36) and equivalent or superior 
to conventional pulmonary rehabilitation in benefiting several 
symptoms of COPD (37).
Meditative movement may also be of benefit in many 
 co-morbidities of COPD, such as heart disease risk factors (38, 
39), hypertension (39, 40), depression and anxiety (26, 41), dia-
betes (42), osteoporosis (43), and muscle weakness (44), as well 
as reduced immune function (45, 46), inflammation (47, 48), 
and autonomic imbalance (49). Many of these beneficial effects 
may happen via the influence of MM on the ANS (26, 50); see 
Figure 3.
study Aims
To evaluate COPD-related health factors in FA exposed to SHCS 
while flying, and to determine the effects of digitally delivered 
MM training on these factors.
There are three sub-aims, relating to the three main aspects 
of the study:
 (1) To investigate the hypothesis that COPD-related pulmonary 
and other symptoms in SHCS-exposed FA are part of a 
syndrome of related disorders.
 (2) To determine that MM practices are most suited to and effec-
tive for ameliorating pulmonary dysfunction and related 
health problems in FA exposed to SHCS.
 (3) To conduct a randomized controlled trial (RCT) to deter-
mine whether this specifically adapted MM training can be 
FIGUrE 1 | reciprocal influences of core coPD pathology and the co-morbidities of coPD.
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effectively delivered digitally, providing the benefits of MM 
without face-to-face instruction being necessary.
MEtHoDs
overall structure of the study
This study has three stages: Screening, Selection, and RCT. 
Screening will continue throughout the study and will gather data 
as well as serving to provide participants for the other Selection 
and RCT stages. The RCT will follow the Selection stage. All 
aspects of this study have been approved by the Dartmouth 
IRB. Additionally, this study is registered at ClinicalTrials.gov 
Identifier: NCT02612389. https://clinicaltrials.gov/ct2/show/
NCT02612389/
Screening
To screen a cohort of FA exposed to SHCS for a range of biomark-
ers and symptoms to determine whether symptom clusters exist 
that suggest a syndromal entity.
Rationale
Flight attendants exposed to SHCS have been observed to display 
a wide range of respiratory, functional, inflammatory, autonomic, 
cardiovascular, affective, and other symptoms. The possible 
relationship between these symptoms has not previously been 
explored. We hypothesize that these symptoms may be correlated 
and form a syndromal entity.
Selection
To determine which of a variety of possible MM exercises are most 
effective in improving specific outcome measures, most enjoy-
able, and most likely to be practiced in a cohort of FA exposed 
to SHCS and having a degree of pulmonary dysfunction. This is 
done by conducting a 16-week in-person MM training program 
that is held in the Northeastern region of the US. Participants 
provide extensive feedback on the exercises.
Rationale
Meditative movement offers an inexpensive intervention that 
could benefit pulmonary symptoms and other related symptoms, 
through its effect on the ANS, cardiovascular, and immune sys-
tems. However, there is a large body of possible MM exercises, 
and there has been no investigation of the relative effectiveness, 
acceptability, and compliance among FA for the many MM 
exercises that are traditionally recommended for COPD-related 
symptoms. To our knowledge, no other study has attempted to 
evaluate a wide range of MM practices to determine which are 
most appropriate for the population being studied.
Randomized Controlled Trial
To develop a DVD or other digital form for delivering the selected 
exercises that have proven to most appropriate for this popula-
tion, and to test by RCT the effectiveness of this digital format 
in improving specified outcome measures in a group of FA with 
FIGUrE 2 | relationships of autonomic dysfunction to the co-morbidities of coPD.
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pulmonary dysfunction and exposed to SHCS, as compared to 
a matched attention control group who will watch educational 
digital material of similar length.
Rationale
Selecting appropriate exercises and providing face-to-face 
instruction in MM offers significant difficulty due to the lack of 
trained teachers in most areas of the country and the practical 
demands of attending classes. A digitally delivered format would 
make this intervention much more accessible, and an RCT will 
evaluate the effectiveness of this intervention.
Participants
Recruitment
Flight attendants were recruited from the Northeastern region 
and other areas of the US for the Selection stage; the Screening and 
RCT stages will involve recruitment throughout the continental 
US in locations convenient to data collection points. Primary 
outreach is through existing FA organizations and networks, 
social media, and FA publications, as well as in conjunction with 
the Harvard Flight Attendant Health Study. Social media support 
is also provided by Department of Health Behavior at the Roswell 
Park Cancer Institute in Buffalo, NY, USA.
Randomization and Blinding
The Screening and Selection stages of this study do not use a 
control group; blinding and randomization are, therefore, not 
necessary. In the RCT, participants will be stratified by gender, 
age, and severity of pulmonary dysfunction and randomized to 
an intervention groups and an attention control, using the covari-
ate adaptive randomization method (51). This method accom-
modates recruitment and testing over an extended period of time. 
Full blinding of participants to intervention is not possible under 
these circumstances; however, all scoring of tests will be done by 
assistants blinded as to participant group.
Inclusion Criteria
The Screening stage of the study acts both to collect participant 
baseline data and to determine eligibility for the Selection and 
RCT stages.
FIGUrE 3 | Hypothesized pathways of direct and indirect influence of MM on co-morbidities of coPD.
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All participants must be current or former non-smoker FAs 
employed by a US carrier for at least 5 years while smoking was 
permitted in the aircraft cabin. They must have a score of above 5 
on the COPD assessment test (CATest); this will eliminate those 
with no detectable pulmonary issues. A score of 5 is a low score, 
indicating minimal level of pulmonary dysfunction.
Many FA exposed to SHCS have detectable pulmonary abnor-
malities despite not meeting Gold criteria for mild COPD (2); we 
wish to include this population, since they are likely at risk for 
the future development of COPD or its co-morbidities. We will 
eliminate any participants not meeting at least one of the follow-
ing spirometric criteria: ratio of forced expiratory volume in 1 s 
to forced vital capacity (FEV1/FVC) < 0.70; OR forced expiratory 
flow (FEF) at 25–75%, volume <80% of predicted normal; OR FEF 
at 50%, volume <80% of predicted normal; OR FEF at 75%, volume 
<80% of predicted normal. We will follow procedures as described 
by Arjomandi et al. (2) for determining normal FEF values.
Participants must be lifetime non-smokers, defined as hav-
ing smoked <100 cigarettes in their lifetime. They must have 
a device on which to listen to audio or watch video instruction 
and be willing to do so; for the RCT portion of the study, capac-
ity to watch online or DVD videos is required. Those who are 
pregnant, or who plan to become pregnant during the study, 
are excluded. Patients with cognitive impairment, severe emo-
tional problems, or who are unable physically to perform the 
exercises are excluded. Participants will be asked not to modify 
their lifestyle significantly during the study period apart from 
the practice required by the study. Participants must all sign 
informed consent forms.
Sample Size
The Screening stage of this study has no limit on number of 
participants. For the Selection and RCT stages of the study, we 
determined that, based on a predicted difference of 46 m in the 
6-min walk test (6MWT) and an assessment of previous similar 
studies of MM for COPD, this study required a sample size of 
20  participants in each group to achieve a statistical power of 
80% at a significance level of 5%. To compensate for anticipated 
dropout, we recruited a total of 27 participants into the Selection 
group. On the basis of our experience of a high dropout and 
non-compliance rate in the Selection stage (~40%), we intend to 
recruit 120 participants for the RCT, 60 for each group.
Interventions
The Screening stage of the study involves no intervention. In the 
Selection stage, the MM intervention is given in person in small 
groups (between 3 and 7), in 3-h classes, spaced 2–4 weeks apart, 
in locations convenient to the participants, for a total of 18 h of 
contact time over 4 months. Participant feedback will be solicited 
as to the subjective effectiveness, enjoyability, and likelihood of 
regular practice of each specific exercise.
The MM classes will be taught by one of the authors, Peter 
Payne, a Qigong teacher with over 40  years experience. In the 
classes, rather than teaching rote movements, the purpose and 
philosophy behind each exercise is explained. Suggestions are 
made as to how to set up a regular practice and how to integrate 
the exercises into everyday life. The participants are encouraged to 
ask questions and make comments on the exercises; all questions 
and comments are recorded in writing at the time. Individual 
attention is given to the needs of each participant, and written 
and audio explanations are also available to participants online. 
(Please see the Supplementary Material for the description of 
exercises from which we draw.)
The RCT stage of the study will involve the design of a digitally 
delivered intervention based on the exercises determined in the 
Selection stage to be most helpful. The intervention may be 
delivered on a DVD or through a web site. The goal will be to 
simulate as closely as possible the experience of attending a class 
through the development of innovative methods, such as com-
puter animation, branching path selection, and user-controlled 
sequencing. Participants in the RCT will also have access to audio 
and written materials. Attention control subjects in the RCT will 
receive equivalent digitally delivered health education materials.
safety considerations
Very few studies of MM have reported significant risks (52) and 
we do not anticipate any ill effects. Nevertheless, participants 
are instructed to discontinue the exercise immediately if they 
experience any of the following: dizziness, rapid or irregular 
heart-beat, sudden or excessive dyspnea, chest pain, significant 
pain anywhere in the body, and headache. In addition, during 
the classes we carefully monitor the participants for signs of 
distress, including facial paleness or redness, rapid breathing, 
sweating, or jerky movement. Any data gathered that suggest 
possible need for medical attention are drawn to the attention 
of the participants.
outcomes
These are the outcome measures to be used in the Screening stage 
of the study as well as to evaluate the effects of the MM practices 
in the Selection and RCT stages. The broad range of outcome 
measures will allow us to examine correlations between a wide 
range of variables representing a number of different physiologi-
cal and psychological systems that may be involved in COPD and 
its co-morbid conditions.
Primary Outcome Measures
Six-minute walk test
Change in high sensitivity C-reactive protein (hs-CRP)
Secondary Outcome Measures
Blood pressure (BP) (pre- and post-6MWT),
Heart rate (HR) (pre- and post-6MWT),
Blood oxygen saturation,
Spirometry FVC, FEV1, FEF 25–75,
Compass 31 (Autonomic function self-report),
Zung Depression Inventory,
Zung Anxiety Inventory,
COPD Assessment Test (CATest),
FA Health Questionnaire,
Multidimensional Assessment of Interoceptive Awareness 
(MAIA),
Borg Dyspnea Scale,
Heart Rate Variability (HRV),
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2 Ewing tests,
Urine analysis (melatonin and cortisol),
Saliva analysis (diurnal cortisol), and
Blood (fingerprick) analysis.
All tests are administered by trained researchers. Blood, urine, 
and saliva analysis provided by ZRT Laboratory, Beaverton, 
OR, USA.
outcome Measurement Details
General Health
Flight Attendant Health Questionnaire
This was developed by Dr. Eileen McNeely at the Harvard School 
of Public Health. Its use provides us with a health and FA-related 
occupational history and enables us to compare our study results 
with those of Dr. McNeely.
Functional Ability
Exercise endurance and tolerance is evaluated by the 6MWT fol-
lowed by the Borg Dyspnea inventory. This is used as our principal 
outcome measure since it is a well-recognized measure of overall 
functional ability. The walk is conducted on an indoor level sur-
face free of obstructions. Research assistants are on hand to assist 
participants with any difficulties. Maximum distance walked in 
6 min is recorded (53–55). The difference in scoring from baseline 
to the end of study is calculated for each participant. The Borg 
Dyspnea Inventory, a well-established instrument for measuring 
respiratory distress, is administered following the 6MWT. The 
6MWT is subject to variation due to motivation; the addition of 
the Borg instrument increases the reliability of the test.
Respiratory Health
The COPD Assessment Test
The CATest is used as an initial recruitment screening as well as 
an outcome measure. Volunteers must score above 5 for inclu-
sion in the study. Its main purpose is to eliminate those with no 
appreciable respiratory dysfunction.
Spirometry
FEV1/FVC and Flow/Volume Curves
Forced expiratory volume in 1 s to forced vital capacity and Flow/
Volume Curves are used as part of the inclusion criteria (see 
above under inclusion criteria), and to determine the degree of 
pulmonary dysfunction. We use specific validated spirometric 
cut points (56). We record FEV1/FVC ratio and Flow/Volume 
Curves using the EasyOne Plus Frontline spirometry system. 
FEV1/FVC is a standard measurement used to determine the 
GOLD grade of COPD. The Flow/Volume Curves indicate the 
degree of pulmonary dysfunction; participants with no detectable 
pulmonary dysfunction are excluded from the study. The differ-
ences in scoring from baseline to specific intervals are calculated 
for each participant.
Cardiovascular Measures
Blood Pressure and Heart Rate
Blood pressure and HR are measured at the beginning of each 
testing period and before and after the 6MWT by a trained 
technician using standard clinical instruments. Cardiac R-R 
intervals are recorded over the entire testing period (about 1½ h) 
using a commercially available system, the Holter myPatch 24-h 
single channel AMS3000 from DMS-Services, Los Angeles, CA, 
USA. This is a non-intrusive device, using two electrodes. Due to 
problems with availability, this measure was not included with 
some participants during the Selection stage of the study only. 
Blood oxygen saturation is also measured, using a Choicemmed 
Oxywatch Fingertip Pulse Oximeter.
Autonomic Condition
Heart rate Variability
Subjects are asked to sit quietly for 10 min. In post-analysis, the 
HR data collected during these periods is used to calculate HRV. 
HRV data will be analyzed using software provided by the manu-
facturer: CardioScan II, version 12.4.0054a, from DMS Software, 
Los Angeles, CA, USA. Time domain (SDNN, RMSSD) and 
frequency domain [power spectral density (PSD)] analysis meth-
ods will be used. Dr. Phyllis Stein, Director of the Washington 
University School of Medicine HRV Lab, will serve as a consult-
ant on HRV analysis and interpretation. HRV measurements are 
only available for a subset of participants in the Selection stage 
due to delayed availability of HR monitors; monitors will be fully 
available during the RCT stage.
Ewing Tests
The Ewing tests evaluate cardiac autonomic function by measur-
ing the response of HR or blood pressure to a physical challenge. 
We will administer two of the battery of five Ewing Tests: deep 
breathing heart rate challenge (DBHR) and lying to standing 
blood pressure challenge (LSBP). DBHR has been determined to 
be the most significant of the Ewing tests, carrying 80% of the 
significance. To measure this, participants will be asked to breathe 
deeply for three 1-min periods at a rate of six times a minute; 
post-analysis using recorded R-R intervals will enable evaluation 
of HR response to challenge, which is a measure of the integrity of 
the sympathetic branch of cardiac autonomic control. To measure 
LSBP, the systolic blood pressure change from supine to standing 
is measured. This gives an indication of cardiac parasympathetic 
function. Comparing the results from HR, BP, HRV, DBHR, 
and LSBP will allow a more accurate evaluation of the cardio- 
respiratory autonomic system than any one of them taken alone. 
Full Ewing test results are only available for a subset of participants 
due to problems with availability of the heart monitors.
COMPASS 31
In addition, we administer the COMPASS 31, a questionnaire for 
detecting dysfunction in many aspects of the ANS.
Affective State
Zung Anxiety and Depression Inventories
These evaluate the degree of affective disturbance. They are both 
well validated and widely used instruments. Since depression 
and anxiety are significant co-morbidities of COPD, and since 
we speculate that MM intervention will have an impact on them, 
the Zung inventories are relevant.
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Interoceptive Awareness
The Multidimensional Assessment of Interoceptive Awareness 
(MAIA)
The Multidimensional Assessment of Interoceptive Awareness 
(MAIA) is a questionnaire that evaluates the degree of a person’s 
awareness of interoceptive cues, as well as his or her degree of 
comfort with these cues. We believe this is relevant to a person’s 
ability to benefit from the MM intervention.
Biomarkers
Biomarkers include urine, saliva, and blood analysis.
Blood Analysis
Capillary blood drops will be taken from the finger following fin-
gerprick with a lancet, and deposited onto a blood spot card used 
specifically for dried blood spot (DBS) collections. Blood spots are 
dried on the filter card for at least 2 h before closing the cover and 
then further dried overnight at room temperature before storing 
the cards for shipment to ZRT Laboratory. Six-millimeter disks of 
blood spots are punched into 96-well plates and the blood extracted 
with buffers. Extracts are assayed for C-reactive protein (CRP), a 
marker of inflammation, as well as HbA1c (a marker of metabolic 
function), thyroid stimulating hormone, and Vitamin D.
Urine Steroid Hormone and Element Testing
Participants will be asked to provide first morning and then a bed-
time urine samples: these are collected onto an absorbent paper 
strip and dried. They will be instructed in correct procedures for 
this. The sample will later be analyzed at ZRT Lab to determine 
by LC-MS/MS levels of urinary free cortisol, free cortisone, and 
melatonin, and by ICP-MS levels of iodine, bromine, selenium, 
arsenic, cadmium, and mercury (all normalized to creatinine).
Salivary Steroid Hormone Testing
Participants are instructed to provide four saliva samples over the 
course of a day. These samples will be stored frozen and batch-
shipped to ZRT Laboratory and analyzed to determine diurnal 
cortisol levels as well as first morning estradiol, progesterone, tes-
tosterone, and dehydroepiandrosterone (DHEA) by LC-MS/MS.
Dried blood spots, dried urine (DU), and saliva samples are 
mailed to the researchers and stored at −70°C until they can be 
shipped in bulk to ZRT Labs for testing.
This extensive range of biomarkers will allow us to examine 
correlations between levels of function of a wide range of physi-
ological systems and pulmonary dysfunction.
During the Selection and RCT stages of the study, feedback 
will be gathered from participants through written logs, and a 
questionnaire on Survey Monkey. Copies of the forms for the 
written logs and the Survey Monkey questionnaire are available 
as Supplementary Material.
statistical Methods
Descriptive statistics, including mean, SD, and frequency, will 
be used to describe and summarize baseline data. We will also 
compare distributions between intervention and control groups 
in the RCT stage using Wilcoxon rank-sum tests and chi-square 
tests at baseline. An intent-to-treat analysis will be carried out 
where missing data will be handled by multiple imputation 
approach, and linear regression models will be used to compare 
the intervention group with the control group in terms of the 
primary outcomes.
stepwise Methods
Stepwise methods are detailed in Figure 4.
Anticipated results
In the Selection and the RCT stages of this research, it is 
anticipated that subjects in the study will increase endurance as 
demonstrated by an increase in the 6MWT by margins that meet 
or exceed statistical significance. A general marker of inflamma-
tion, hs-CRP, is expected to decrease significantly. Consistent 
with evidence that MM may benefit the ANS, we expect to see 
a decrease in blood pressure. With the larger number of subjects 
in the RCT stage of the study, secondary measures are expected 
to provide data suggesting or discounting relationships between 
ANS function, mood, pulmonary, and immune system functions.
Pitfalls, Artifacts, and troubleshooting
A potential pitfall in this study is the difficulty in recruiting and 
retaining subjects. Our extensive network of contacts among 
FA will facilitate this process, as will our outreach through 
FA-connected social media. The recruitment process can be 
extended in time to assure adequate numbers. In addition, the 
researchers are prepared to travel to locations throughout the 
country as necessary.
Retention of subjects in the second and third stages is another 
concern. It is anticipated that retention will not exceed the 40% 
of the Selection stage of the study, as the exercises to be taught 
are simple and enjoyable. However we are allowing for up to 60% 
drop-out rate. Should dropout be more than anticipated, we will 
need to recruit more subjects, which should prove possible. We 
have maintained good communication with all subjects.
In the Selection stage of the study, any difficulties participants 
have had with the training, including safety-related concerns, 
were explored as a source of information concerning appropriate 
selection of exercises; this was one of the aims of this portion of 
the study.
The smoking status of study participants is queried during the 
recruitment and further during testing for each stage of this study. 
However, additional details of a smoking history have, in a few 
cases, emerged when other data had already been collected on 
these subjects. Outcomes from these subjects will be sequestered 
and reported separately from those who smoked less than 100 
cigarettes in a lifetime.
Due to limited availability of equipment, the wearable ECGs 
were not used in the majority of pre-testing in the Selection stage. 
Changes in HRV are, therefore, not documented. However, other 
measures of cardiovascular autonomic function were made, 
including HR, BP, and changes in these measures in response to 
challenge. These will provide some information about possible 
autonomic changes.
In the Selection stage, we do not use a control group. Since 
the purpose of this portion is to determine that MM exercises 
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FIGUrE 4 | Proposed timeline for the study.
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are most effective and best tolerated, use of a control group would 
not be appropriate. This diminishes the power of results from 
the pre-and post-intervention tests in this portion as it will not 
be possible to determine with certainty whether results are due 
to attention, seasonal or other factors. However, the final RCT 
stage of the study, using an attention/health education control 
group, will provide a well-controlled validation of the effects of 
the selected MM exercises. It is, however, possible that positive 
results from the testing in the Selection stage, followed by nega-
tive results from the RCT stage, would reflect the ineffectiveness 
of digital delivery rather than the ineffectiveness of the interven-
tion. In this case, an RCT testing in-person delivery would be 
indicated.
The 6MWT is known to be influenced by motivation. The use 
of the Borg Dyspnea Inventory is used as a control on this, as it 
indexes amount of effort, and every precaution has been taken 
by the researchers to standardize the administration of the test. 
Nonetheless, in the Selection stage, subjects may be more highly 
motivated in the post-test situation, and this could skew results. 
As mentioned above, the use of a control group in the RCT stage 
will provide a check on these results.
In the RCT stage, compliance is expected to be an issue. We 
plan to be in contact by email, phone, and digital questionnaire 
with all subjects on a weekly basis. We will follow up quickly 
any lapses in communication or reporting of difficulties, so as to 
minimize this issue. Such difficulties arising in this stage will also 
provide further information for future refinement of the delivery 
method and the selection of exercises.
DIscUssIoN
We believe that the ANS may be a link between the various 
 co-morbidities of COPD.
We speculate that COPD-related pulmonary and other 
 co-morbid conditions appearing in FA exposed to SHCS may be 
part of a syndrome of interacting conditions related to disturbed 
autonomic function. The Screening stage of this study will pro-
vide data to test this speculation.
In addition to our primary outcome measures, we are 
gathering a wide range of data, including hormonal biomark-
ers, affective, and autonomic measures. This may allow for the 
formulation of hypotheses for future testing concerning the 
mechanisms of action of MM on pulmonary dysfunction and 
other health conditions. In preliminary data, we are seeing pat-
terns of subclinical morbidities that may provide an improved 
picture of the health care needs of this unique group of work-
ers. It, however, remains to be seen whether these patterns are 
simply age related or unique to this group and their exposure 
to SHCS.
Since MM has been shown to have beneficial effects on many 
of the co-morbid conditions of COPD, possibly by way of its regu-
lating effect on autonomic functioning, this suggests that a single 
approach (MM) might target not only COPD-related respiratory 
symptoms but also many other COPD-related conditions. Future 
studies could determine whether MM could slow the progression 
of pre-COPD conditions to clinical COPD.
Previous trials of the effects of MM have relied on a 
preselected set of exercises, in some cases chosen for their 
traditional relevance to the condition being treated (57) but in 
most cases a traditional general set (30, 32–36). Our study is 
the first to involve a test period in which a wide range of MM 
exercises is evaluated for a specific population. We have already 
observed that participants have trouble setting aside time for 
regular practice. Our approach to MM includes a number of 
practices that can be integrated with the activities of daily life 
(rather than having to be practiced at a certain time), and we 
have found that this form of practice is more acceptable to this 
group of FA.
We experienced an unexpected level of dropout during the 
Selection stage of the study. Given that the average age of par-
ticipants is 69, this should have been anticipated. We have found 
that the provision of exercises that can be integrated into daily 
life, such as simple standing, sitting, walking, and breathing 
practices, increases compliance and appears to reduce dropout. 
We believe that the emphasis on this kind of practice can make 
Asian practices more accessible and appealing to Westerners with 
their busy lifestyles.
Our study explores the possibility of administering an MM 
intervention by digital means. To our knowledge, no other study 
of MM has tested this possibility. Information gained from this 
aspect of the study may provide information about the most 
effective ways of conveying MM training digitally, as well as 
validating the effectiveness of MM for COPD-related pulmonary 
dysfunction. Should our principal hypothesis be supported, 
it would not only open the possibility of a safe, cost-effective 
intervention for those with pulmonary dysfunction, but also 
support the further exploration of digitally delivered MM for 
a wide range of conditions, especially those with a significant 
autonomic component.
trial status
Recruitment for the Screening and evaluation portion of the study 
began in August 2014 and will continue for the duration of the 
study, until mid 2017. Comprehensive data have been gathered 
on more than 60 participants to date, and preliminary analysis 
has begun.
Recruitment for the MM exercise selection portion of the study 
began in October 2014 and will continue through October 2015. 
While 27 participants have been recruited so far into the Selection 
stage, there is concern for assuring that a statistically significant 
number will complete this stage of the study. No adverse events 
have been reported. Post-intervention testing began in July 20 
2015, and is on going.
Preparations for the development of a digitally deliverable 
MM intervention are presently underway, involving developing 
video footage and planning. Recruitment for the RCT portion of 
the study began in October 2015.
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AcroNYMs
6MWT Six-minute walk test A standard test for assessing functional ability, the distance walked in 6 min
ANS Autonomic nervous system Portion of the nervous system controlling those physiological functions outside normal voluntary control
BP Blood pressure
COPD Chronic obstructive pulmonary disease Chronic disease involving obstruction of the small airways
CRP C-reactive protein Biomarker of inflammation
DBHR Deep breathing heart rate One of the battery of 5 Ewing tests for cardiac autonomic dysfunction; the most significant of the 5
DVD Digital video disk Standard vehicle for presenting video
EAC Education activity control A control group engaging in educational activity, in this case watching educational videos
FA Flight attendants
FAMRI Flight attendant medical research institute The foremost organization promoting research into medical problems affecting flight attendants
FEF Forced expiratory flow Spirometric measurement, flow of air during forced exhalation
FEV1 Forced expiratory volume one A measure of lung function: the maximum volume of air breathed out in a forcible exhalation in 1 s
FVC Forced vital capacity A measure of lung function: the total volume of air breathed out in a complete forcible exhalation
GOLD Global initiative on obstructive lung disease A research and information group that is the principal global authority on the nature and treatment of COPD
HR Heart rate
HRV Heart rate variability Degree of variability over time (especially in synchrony with the breathing) of the R-R, or beat-to-beat, heart 
rate; since this variation of heart rate is under control of the parasympathetic nervous system, HRV offers a 
way of evaluating this aspect of ANS function
LSBP Lying standing blood pressure A Ewing test of the blood pressure response to going from lying to standing
MAIA Multidimensional assessment of interoceptive 
awareness
A questionnaire designed to evaluate several dimensions of interoceptive awareness
MM Meditative movement A newly identified form of exercise characterized by a meditative state of mind, deep relaxation, movement, 
and attention to the breathing. Qigong and Yoga are the best known examples
NHANES National health and nutrition examination 
survey
PI Principal investigator
PSD Power spectrum density A measure of frequency distribution used to evaluate HRV
QOL Quality of life A general measure of the quality of a patients daily life
RCT Randomized controlled trial The premier form of research study in which participants are randomly assigned to control or intervention 
group for the purpose of objective assessment of an intervention
RMSSD Root mean square standard deviation A statistical method used in this study for the analysis of HRV data
SDNN Standard deviation A statistical method used in this study for the analysis of HRV data
SHCS Second-hand cigarette smoke Cigarette smoke inhaled by someone other than the smoker; ambient smoke not inhaled directly through 
the cigarette
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